British biotech company Quotient Therapeutics raises $50M in initial funding

Quotient Therapeutics has developed a Somatic Genomics platform that unveils a new universe of genetic variation to create transformational medicines. Here are details of Quotient Therapeutics‘s latest funding round :

🚀 Launch

🏭 Industry



Geoffrey von Maltzahn (CEO)

💸 Funding & Investors

INVESTMENT (Novembre 2023)$50 million
INVESTORS (Novembre 2023)led by Flagship Pioneering

🎯 Funding purpose

Advance development of its platform.

🌐 Country HQ

UK (Cambridge)

Leave a Reply

Your email address will not be published.